R&D channel feed

Madri­gal’s got more pos­i­tive da­ta for resme­tirom, plus news from Ali­gos and North­Sea

Last year

Neu­ro­crine ax­es Take­da-part­nered de­pres­sion pro­gram, switch­es fo­cus for seizure drug af­ter PhII fail­ures

Last year

Val­ne­va re­ceives first chikun­gun­ya vac­cine ap­proval af­ter two month de­lay to FDA re­view

Last year
FDA+

No­var­tis plans BTK in­hibitor fil­ing in chron­ic spon­ta­neous ur­ticaria as Celldex’s mid-stage da­ta ex­cite in­vestors

Last year

Re­cur­sion and Bay­er to wind down fi­bro­sis R&D pact af­ter three years, re­fo­cus­ing on can­cer

Last year
Deals

Atara Bio­ther­a­peu­tic­s' stock drops near­ly 50% af­ter PhII tri­al fail in MS

Last year
Cell/Gene Tx

Ful­ly syn­thet­ic genome nears com­ple­tion in a step to­ward un­rav­el­ing ge­net­ic mys­ter­ies

Last year
Discovery
In Focus

As­traZeneca spot­lights bis­pecifics in can­cer as it rais­es guid­ance, while prun­ing rare dis­ease pipeline

Last year
Pharma

As­traZeneca puts down $185M up­front for PhI oral GLP-1 as it shoots for next-gen win

Last year
Deals

Lyell lays off 25% of staff and CMO leaves as com­pa­ny fore­shad­ows first clin­i­cal da­ta next year

Last year
People

BioN­Tech’s ‘ex­ten­sive’ can­cer pipeline comes in­to fo­cus, with em­pha­sis on AD­Cs

Last year
Deals

Gilead re­ports 'flat' Q3 rev­enues, cuts PhI­II Covid tri­al

Last year
Pharma

Bay­er un­veils big changes to busi­ness and head­count to ad­dress ‘not ac­cept­able’ per­for­mance

Last year
Pharma

Im­bria touts PhII suc­cess in hy­per­trophic car­diomy­opa­thy, adding fu­el to over­all ef­fi­ca­cy pro­file

Last year

Gilead, Ar­cus’ PhII gas­troe­sophageal can­cer da­ta ar­gue for TIG­IT an­ti­body drug class po­ten­tial

Last year

Ven­tyx Bio­sciences' stock drops over 70% af­ter ax­ing pso­ri­a­sis drug pro­gram

Last year

No­var­tis slots PhI car­dio­vas­cu­lar can­di­date in­to pipeline, pay­ing Ko­re­an part­ner $80M up­front

Last year
Deals

Ver­tex dis­con­tin­ues a PhII rare dis­ease drug, sets ear­ly 2024 time­line for piv­otal non-opi­oid pain pill read­out

Last year
Pharma

Ko­di­ak 're­boot­s' Eylea com­peti­tor af­ter pos­i­tive da­ta in di­a­bet­ic vi­sion loss tri­al

Last year

Moon­Lake’s stock falls more than 20% de­spite mid-stage suc­cess in pso­ri­at­ic arthri­tis

Last year

RAPT Ther­a­peu­tics bol­sters part­ner search with PhII da­ta on small mol­e­cule-Keytru­da com­bo

Last year

As­traZeneca, Ele­don and Alpine spell out kid­ney pro­gram suc­cess­es: ASN roundup

Last year

Pfiz­er to cut 200 jobs at Michi­gan plant that makes Covid prod­ucts

Last year
People
Pharma

In ear­ly look at ASH ab­stracts, BeiGene touts Brukin­sa da­ta, Cel­lec­tis com­pares in-house CAR-T to CD­MO CAR-T

Last year
First page Previous page 64656667686970 Next page Last page
A service from the Financial Times